“We expect to read out six additional phase three trials for retreutide in 2026, including the remainder of the core registration package for both the TRIUMPH obesity program and the Transcend type two diabetes program.”

In context

“an average of 4.5 points, representing a 76% reduction in pain, and this was accompanied by a significant improvement in physical function. Impressively, more than one in eight retreutide-treated patients were completely free from knee pain at the end of this trial. The safety profile was generally consistent with other incretins, with gastrointestinal events being most common. We observed higher discontinuation rates due to adverse events in people with lower baseline BMI, including participants who discontinued for perceived excessive weight loss. As shown on slide 17, patients with a baseline BMI of 35 or higher, which represented 84% of the trial population, had discontinuation rates due to adverse events consistent with those observed in clinical trials of other injectable incretins. We expect to read out six additional phase three trials for retreutide in 2026, including the remainder of the core registration package for both the TRIUMPH obesity program and the Transcend type two diabetes program. Also in Q4, we started a phase three trial in high-risk metabolic dysfunction-associated steatotic liver disease, MACELD, studying retreutide as well as tirzepatide for treatment of this disease. We're planning to submit the results of the Core TRIUMPH program in 2026 to support applications for overweight and obesity, obstructive sleep apnea, and osteoarthritis of the knee for retreutide. Based on the data we've seen so far, depending on these upcoming data readouts, we believe retreutide may have the potential to become a new treatment option for patients with significant weight loss with certain complications. Moving to tirzepatide, we're pleased that Zepbound was recently approved in the US in a multi-use QuickPen device. This presentation of tirzepatide is already available in many c”